Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: global statistics for 2020 and 2040. The Breast. 2022;66:15–23.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Agha A, Wang X, Wang M, Lehrer EJ, Horn SR, Rosenberg JC, Trifiletti DM, Diaz R, Louie AV, Zaorsky NG. Long-term risk of death from heart disease among breast cancer patients. Front Cardiovasc Med. 2022;9: 784409.

Article  PubMed  PubMed Central  Google Scholar 

Oikawa M, Ishida T, Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. J Cardiol. 2023;81(3):253–9.

Article  PubMed  Google Scholar 

Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M, Butler J, Carapetis J, Ceconi C, Chioncel O, et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail. 2022;24(1):143–68.

Article  PubMed  Google Scholar 

Chung R, Ghosh AK, Banerjee A: Cardiotoxicity: precision medicine with imprecise definitions. In., vol. 5: Archives of Disease in childhood; 2018: e000774.

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal - Cardiovascular Imaging. 2022;23(10):e333–465.

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O et al: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022, 24(1):4-131.

Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(4):270–5.

Article  PubMed  Google Scholar 

Lanza O, Ferrera A, Reale S, Solfanelli G, Petrungaro M, Tini Melato G, Volpe M, Battistoni A: New insights on the toxicity on heart and vessels of breast cancer therapies. Med Sci (Basel) 2022, 10(2).

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66(1):43–73.

Article  PubMed  Google Scholar 

Lee GA, Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, Asteggiano R, Szmit S, Cohen-Solal A, Abdin A, et al. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes. 2022;9(1):1–7.

Article  PubMed  PubMed Central  Google Scholar 

Alexandraki A, Papageorgiou E, Zacharia M, Keramida K, Papakonstantinou A, Cipolla CM, Tsekoura D, Naka K, Mazzocco K, Mauri D et al: New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review. Cancers (Basel) 2023, 15(13).

Di Lisi D, Manno G, Madaudo C, Filorizzo C, Intravaia RCM, Galassi AR, Incorvaia L, Russo A, Novo G: Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices. Int J Cardiovasc Imaging 2023.

Kar J, Cohen MV, McQuiston SA, Malozzi CM. Can global longitudinal strain (GLS) with magnetic resonance prognosticate early cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients, a prospective study? Magn Reson Imaging. 2023;97:68–81.

Article  CAS  PubMed  Google Scholar 

Lim A, Jang H, Jeon M, Fadol AP, Kim S. Cancer treatment-related cardiac dysfunction in breast cancer survivors: a retrospective descriptive study using electronic health records from a Korean tertiary hospital. Eur J Oncol Nurs. 2022;59: 102163.

Article  PubMed  Google Scholar 

Liu W, Li W, Li H, Li Z, Zhao P, Guo Z, Liu C, Sun L, Wang Z. Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction. BMC Cardiovasc Disord. 2022;22(1):548.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mauro C, Capone V, Cocchia R, Cademartiri F, Riccardi F, Arcopinto M, Alshahid M, Anwar K, Carafa M, Carbone A et al: Cardiovascular side effects of anthracyclines and HER2 inhibitors among patients with breast cancer: a multidisciplinary stepwise approach for prevention, early detection, and treatment. J Clin Med 2023, 12(6).

Okushi Y, Saijo Y, Yamada H, Toba H, Zheng R, Seno H, Takahashi T, Ise T, Yamaguchi K, Yagi S et al: Effectiveness of surveillance by echocardiography for cancer therapeutics-related cardiac dysfunction of patients with breast cancer. J Cardiol 2023.

Ositelu K, Trevino A, Tong A, Chen MH, Akhter N: Challenges in cardiovascular imaging in women with breast cancer. Curr Cardiol Rep 2023.

Terui Y, Sugimura K, Ota H, Tada H, Nochioka K, Sato H, Katsuta Y, Fujiwara J, Harada-Shoji N, Sato-Tadano A, et al. Usefulness of cardiac magnetic resonance for early detection of cancer therapeutics-related cardiac dysfunction in breast cancer patients. Int J Cardiol. 2023;371:472–9.

Article  PubMed  Google Scholar 

Thavendiranathan P, Shalmon T, Fan CS, Houbois C, Amir E, Thevakumaran Y, Somerset E, Malowany JM, Urzua-Fresno C, Yip P, et al. Comprehensive cardiovascular magnetic resonance tissue characterization and cardiotoxicity in women with breast cancer. JAMA Cardiol. 2023;8(6):524–34.

Article  PubMed  PubMed Central  Google Scholar 

Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25(32):5121–7.

Article  PubMed  Google Scholar 

White J, Byles J, Williams T, Untaru R, Ngo DTM, Sverdlov AL. Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences. Cardiooncology. 2022;8(1):14.

PubMed  PubMed Central  Google Scholar 

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13(3):176-181.

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP et al: Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014, 106(9).

Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;36:67–73.

Article  Google Scholar 

Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–8.

Article  PubMed  PubMed Central  Google Scholar 

Liu L, Suo T, Shen Y, Geng C, Song Z, Liu F, Wang J, Xie Y, Zhang Y, Tang T, et al. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res. 2020;29(11):3009–15.

Article  PubMed  Google Scholar 

Munn Z, Pollock D, Khalil H, Alexander L, Mclnerney P, Godfrey CM, Peters M, Tricco AC. What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis. JBI Evidence Synthesis. 2022;20(4):950–2.

Article  PubMed  Google Scholar 

Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005;8(1):19–32.

Article  Google Scholar 

Peters M, Godfrey C, McInerney P, Munn Z, Tricco A, Khalil H: Chapter 11: scoping reviews (2020 version). In: JBI Manual for Evidence Synthesis. edn. Edited by Aromataris E MZ: JBI; 2020.

Munn Z, Peters MD, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC medical research methodology. 2018;18:1–7.

Article  Google Scholar 

Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, Pollock D, Tricco AC, Munn Z. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953–68.

Article  PubMed  Google Scholar 

Bohdan M, Kowalczys A, Mickiewicz A, Gruchala M, Lewicka E: Cancer therapy-related cardiovascular complications in clinical practice: current perspectives. J Clin Med 2021, 10(8).

Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–63.

Article  PubMed  Google Scholar 

Bozkurt B, Coats A, Tsutsui H: Universal definition and classification of heart failure. J Card Fail 2021.

Aldiab A. Cardiotoxicity with adjuvant trastuzumab use in breast cancer: a single institution»s experience. J Saudi Heart Assoc. 2010;22(3):133–6.

Article  PubMed  PubMed Central  Google Scholar 

Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, Paton V, Holmgren E, Mahaffey KW. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416–21.

Article  CAS  PubMed  Google Scholar 

Polk A, Shahmarvand N, Vistisen K, Vaage-Nilsen M, Larsen FO, Schou M, Nielsen DL: Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open 2016, 6(10).

Clark RA, Marin TS, McCarthy AL, Bradley J, Grover S, Peters R, Karapetis CS, Atherton JJ, Koczwara B. Cardiotoxicity after cancer treatment: a process map of the patient treatment journey. Cardiooncology. 2019;5:14.

PubMed  PubMed Central  Google Scholar 

Anjos M, Fontes-Oliveira M, Costa VM, Santos M, Ferreira R. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sci. 2021;280: 119760.

Article  CAS  PubMed